Union Ministry of Health and Family Welfare has notified amendments to the Drugs Rules, 1945, empowering licensing authorities to debar applicants who submit fake or fabricated data in support of regulatory applications.

The move is aimed at strengthening the integrity and transparency of India's drug regulatory system.

The amendments, notified through G.S.R. 756(E) dated October 16, 2025, introduce stricter punitive measures in addition to the existing enforcement provisions under the Drugs and Cosmetics Act, 1940.

Under the new provisions, companies or entities found to have submitted fabricated data can be barred from filing further applications with the concerned regulatory authority—either at the Central or State level—for a specified period. The debarment will apply to applications submitted under various provisions of the Drugs Rules, 1945.

Previously, applicants submitting false or fabricated data were subject to actions such as rejection of applications or cancellation of existing licences. The latest amendment expands the regulatory toolkit by allowing authorities to prevent repeat offenders from seeking fresh approvals. 

The ministry has incorporated procedural safeguards, including the issuance of a show-cause notice before any debarment order is passed. Applicants will also have the right to appeal against such decisions.

According to the ministry, the submission of scientifically valid data is fundamental to assessing the quality, safety and efficacy of medicines. The use of fake or fabricated information undermines the credibility of the regulatory process, raises concerns about drug quality and could potentially jeopardise public health. 

The amendment is intended to deter misconduct, strengthen accountability among pharmaceutical applicants and ensure that regulatory approvals are based on reliable scientific evidence.

The notification is part of the government's broader efforts to align India's pharmaceutical regulatory framework with global best practices. It seeks to encourage compliance among drug manufacturers and distributors while ensuring that instances of malpractice are dealt with firmly.

The ministry said the reforms complement ongoing regulatory initiatives aimed at enhancing oversight, promoting ethical practices and imposing stricter penalties on entities that violate regulatory norms.